GlassScriptPhysician profile
Taylor Noel Johnson
NPI 1023770757
$1,748.46
in general payments reported to CMS, 2019-2025
23 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.99 · 2022: $439 · 2023: $397 · 2024: $540 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.76 |
| Education | $307.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $429.39 | 2022-2024 | |
| Janssen Biotech, INC. | $216.14 | 2023-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $188.64 | 2023-2025 | Provenge |
| Sumitomo Pharma America, INC. | $182.67 | 2023-2025 | Gemtesa, Orgovyx |
| Axonics, INC. | $124.68 | 2022-2024 | Bulkamid, Axonics |
| Medtronic, INC. | $110.62 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $65.40 | 2022-2025 | Lynparza, Keytruda, Welireg |
| Progenics Pharmaceuticals, INC. | $45.54 | 2024-2025 | |
| Tolmar Pharmaceuticals, INC. | $45.31 | 2021-2022 | |
| Valencia Technologies Corporation | $41.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.60 | 2022-2023 | |
| Teleflex LLC | $37.48 | 2023 | Urolift |
| Novo Nordisk INC | $31.90 | 2024 | Rivfloza |
| Urovant Sciences INC | $29.56 | 2022 | |
| Urogen Pharma, INC. | $28.31 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.48 | 2023 | |
| Pfizer INC. | $17.56 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.64 | 2022 | |
| Verity Pharmaceuticals INC. | $16.31 | 2023 | Trelstar |
| Myriad Genetic Laboratories, INC. | $16.20 | 2023 | Prolaris |
| Ferring Pharmaceuticals INC. | $15.98 | 2023 | Adstiladrin |
| Olympus America INC. | $14.36 | 2025 | Itind System |
| Tolmar, INC. | $13.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.